Amneal Pharmaceuticals Secures FDA Approval for Lanreotide Injection

04:36 PM EDT, 09/18/2026 (MT Newswires) -- Amneal Pharmaceuticals (AMRX) said Friday that the US Food and Drug Administration approved its lanreotide injection, 120 mg/0.5 mL. The company said it will immediately launch the product, which references SOMATULINE Depot and received Competitive Generic Therapy designation from the FDA. Lanreotide injection is indicated for the treatment of acromegaly, advanced gastro-enteropancreatic neuroendocrine tumors and carcinoid syndrome, according to a statement.